236 related articles for article (PubMed ID: 33762352)
1. Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector Functions.
Hajaj E; Zisman E; Tzaban S; Merims S; Cohen J; Klein S; Frankenburg S; Sade-Feldman M; Tabach Y; Yizhak K; Navon A; Stepensky P; Hacohen N; Peretz T; Veillette A; Karni R; Eisenberg G; Lotem M
Cancer Immunol Res; 2021 Jun; 9(6):637-650. PubMed ID: 33762352
[TBL] [Abstract][Full Text] [Related]
2. SLAMF6 deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint.
Hajaj E; Eisenberg G; Klein S; Frankenburg S; Merims S; Ben David I; Eisenhaure T; Henrickson SE; Villani AC; Hacohen N; Abudi N; Abramovich R; Cohen JE; Peretz T; Veillette A; Lotem M
Elife; 2020 Mar; 9():. PubMed ID: 32122464
[TBL] [Abstract][Full Text] [Related]
3. Soluble SLAMF6 Receptor Induces Strong CD8
Eisenberg G; Engelstein R; Geiger-Maor A; Hajaj E; Merims S; Frankenburg S; Uzana R; Rutenberg A; Machlenkin A; Frei G; Peretz T; Lotem M
Cancer Immunol Res; 2018 Feb; 6(2):127-138. PubMed ID: 29305520
[TBL] [Abstract][Full Text] [Related]
4. SLAMF6 as a Regulator of Exhausted CD8
Yigit B; Wang N; Ten Hacken E; Chen SS; Bhan AK; Suarez-Fueyo A; Katsuyama E; Tsokos GC; Chiorazzi N; Wu CJ; Burger JA; Herzog RW; Engel P; Terhorst C
Cancer Immunol Res; 2019 Sep; 7(9):1485-1496. PubMed ID: 31315913
[TBL] [Abstract][Full Text] [Related]
5. Clinical and immunological relevance of SLAMF6 expression in the tumor microenvironment of breast cancer and melanoma.
Oba T; Long MD; Ito KI; Ito F
Sci Rep; 2024 Jan; 14(1):2394. PubMed ID: 38287061
[TBL] [Abstract][Full Text] [Related]
6. SLAMF6 clustering is required to augment T cell activation.
Dragovich MA; Adam K; Strazza M; Tocheva AS; Peled M; Mor A
PLoS One; 2019; 14(6):e0218109. PubMed ID: 31199820
[TBL] [Abstract][Full Text] [Related]
7. CRISPR-Mediated Triple Knockout of SLAMF1, SLAMF5 and SLAMF6 Supports Positive Signaling Roles in NKT Cell Development.
Huang B; Gomez-Rodriguez J; Preite S; Garrett LJ; Harper UL; Schwartzberg PL
PLoS One; 2016; 11(6):e0156072. PubMed ID: 27258160
[TBL] [Abstract][Full Text] [Related]
8. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
9. Expression and function of SLAMF6 in CD8
Liu B; Zeng L; Shao Y; Fu R
Cell Immunol; 2021 Jun; 364():104343. PubMed ID: 33774556
[TBL] [Abstract][Full Text] [Related]
10. Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation.
Li SY; Liu Y; Xu CF; Shen S; Sun R; Du XJ; Xia JX; Zhu YH; Wang J
J Control Release; 2016 Jun; 231():17-28. PubMed ID: 26829099
[TBL] [Abstract][Full Text] [Related]
11. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.
Lacal PM; Atzori MG; Ruffini F; Scimeca M; Bonanno E; Cicconi R; Mattei M; Bernardini R; D'Atri S; Tentori L; Graziani G
Pharmacol Res; 2020 Sep; 159():104957. PubMed ID: 32485280
[TBL] [Abstract][Full Text] [Related]
12. P2X7 Receptor Activity Limits Accumulation of T Cells within Tumors.
Romagnani A; Rottoli E; Mazza EMC; Rezzonico-Jost T; De Ponte Conti B; Proietti M; Perotti M; Civanelli E; Perruzza L; Catapano AL; Baragetti A; Tenedini E; Tagliafico E; Falzoni S; Di Virgilio F; Norata GD; Bicciato S; Grassi F
Cancer Res; 2020 Sep; 80(18):3906-3919. PubMed ID: 32699136
[TBL] [Abstract][Full Text] [Related]
13. A hematopoietic cell-driven mechanism involving SLAMF6 receptor, SAP adaptors and SHP-1 phosphatase regulates NK cell education.
Wu N; Zhong MC; Roncagalli R; Pérez-Quintero LA; Guo H; Zhang Z; Lenoir C; Dong Z; Latour S; Veillette A
Nat Immunol; 2016 Apr; 17(4):387-96. PubMed ID: 26878112
[TBL] [Abstract][Full Text] [Related]
14. SLAMF6 compartmentalization enhances T cell functions.
Gartshteyn Y; Askanase AD; Song R; Bukhari S; Dragovich M; Adam K; Mor A
Life Sci Alliance; 2023 Feb; 6(2):. PubMed ID: 36622343
[TBL] [Abstract][Full Text] [Related]
15. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
16. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
[TBL] [Abstract][Full Text] [Related]
17. Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo.
Emmrich S; Wang W; John K; Li W; Pützer BM
Mol Cancer; 2009 Aug; 8():61. PubMed ID: 19671150
[TBL] [Abstract][Full Text] [Related]
18. Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.
Mahvi DA; Meyers JV; Tatar AJ; Contreras A; Suresh M; Leverson GE; Sen S; Cho CS
J Immunother; 2015; 38(2):54-61. PubMed ID: 25658614
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral Tcf1
Siddiqui I; Schaeuble K; Chennupati V; Fuertes Marraco SA; Calderon-Copete S; Pais Ferreira D; Carmona SJ; Scarpellino L; Gfeller D; Pradervand S; Luther SA; Speiser DE; Held W
Immunity; 2019 Jan; 50(1):195-211.e10. PubMed ID: 30635237
[TBL] [Abstract][Full Text] [Related]
20. Induction of Progenitor Exhausted Tissue-Resident Memory CD8
León-Letelier RA; Castro-Medina DI; Badillo-Godinez O; Tepale-Segura A; Huanosta-Murillo E; Aguilar-Flores C; De León-Rodríguez SG; Mantilla A; Fuentes-Pananá EM; López-Macías C; Bonifaz LC
Front Immunol; 2020; 11():583382. PubMed ID: 33240271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
